Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TIMP-1 and CEA as biomarkers in third-line treatment with irinotecan and cetuximab for metastatic colorectal cancer.

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine - 1 Jun 2015

Spindler Karen-Lise Garm, Christensen Ib Jarle, Nielsen Hans Jørgen, Jakobsen Anders, Brünner Nils

Abstract excerpt

KRAS wild-type (wt) status determines indication for treatment with combination therapy, including epidermal growth factor receptor (EGFR) inhibitors, but still, the overall response rate in KRAS wt patients is less than 40 %. Consequently, the majority of patients will suffer from substantial side effects and no apparent benefit. Tissue inhibitor of metalloproteinases-1 is a glycoprotein, which regulates...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Camptothecin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoembryonic Antigen

Share to Cetuximab

Share to Disease-Free Survival

Share to Irinotecan

Share to ras Proteins

Share to Tissue Inhibitor of Metalloproteinase-1

Source

Identifiers

PMID: 25608838
DOI: 10.1007/s13277-015-3069-z

Genes

KRAS
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TIMP-1 and CEA as biomarkers in third-line treatment with irinotecan and cetuximab for metastatic colorectal cancer.PMID 25608838Read ↗

TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: a potential novel approach to the treatment of metastatic colorectal cancer.Semantic proximity Read ↗

Serum matrilysin correlates with poor survival independently of KRAS and BRAF status in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximab.Semantic proximity Read ↗

The role of tumor markers and biomarkers in colorectal cancer.Semantic proximity Read ↗

The behavior of matrix metalloproteinases and their inhibitors in colorectal cancer.Semantic proximity Read ↗

Tissue inhibitor of metalloproteinases (TIMP)‐1 creates a premetastatic niche in the liver through SDF‐1/CXCR4‐dependent neutrophil recruitment in miceSemantic proximity Read ↗

TIMP‐1 expression in human colorectal cancer is associated with TGF‐B1, LOXL2, INHBA1, TNF‐AIP6 and TIMP‐2 transcript profilesSemantic proximity Read ↗

Effect of TIMPs and Their Minimally Engineered Variants in Blocking Invasion and Migration of Brain Cancer CellsSemantic proximity Read ↗

Tissue inhibitor of matrix metalloproteinase‐1 expression in colorectal cancer liver metastases is associated with vascular structuresSemantic proximity Read ↗

TIMP-1 Increases Expression and Phosphorylation of Proteins Associated with Drug Resistance in Breast Cancer CellsSemantic proximity Read ↗

Expression level and glycan dynamics determine the net effects of TIMP-1 on cancer progressionSemantic proximity Read ↗

Clinical characteristics of TIMP2, MMP2, and MMP9 gene polymorphisms in colorectal cancer.Semantic proximity Read ↗

The activity of a designer tissue inhibitor of metalloproteinases (TIMP)-1 against native membrane type 1 matrix metalloproteinase (MT1-MMP) in a cell-based environment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.